Article

Patient's Personality Influences Chronic Back Pain

Patients' levels of anxiety and defensiveness are associated with how they view their chronic back pain, a new study showed.

Patients’ levels of anxiety and defensiveness are associated with how they view their chronic back pain, a new study showed.

Researchers from Manchester Metropolitan University in England separated 70 participants into one of 4 groups based on personality type: defensive high-anxious (DHA), high-anxious (HA), repressors (REP), or low-anxious (LA). Differences between the groups attentional bias were presented at the 34th Annual American Pain Society Scientific Meeting in Palm Springs, CA.

“There is extensive research investigating REP individuals within the general and chronic illness populations,” the study explained. “However, there is limited research investigating DHA individuals in a musculoskeletal pain population.”

The subjects were shown multiple sets of a neutral image alongside an emotion-provoking image — specifically related to back pain. The study explained that the dot probe task was made up of 20 practice trials and 250 experimental trials.

Although the HA group did not show bias, the other 3 displayed clear differences. “Post hoc analysis showed the DHA group differed significantly from both the HA and REP individuals,” the report confirmed.

Using the Marlow-Crowne Social Desirability scale and the subscale State Trait Anxiety Inventory, the authors revealed the following:

  • DHA Group: Significant attentional bias for threatening images compared to neutral
  • HA Group: Showed no bias
  • REP Group: Significant attentional bias for positive images compared to neutral

The authors noted that the difference between the DHA and HA groups should be highlighted since the results suggest that the defensiveness factor plays a key role in attentional bias towards back pain.

“The demonstration of an attentional bias to threatening information could explain why defensive high-anxious individuals are more likely to show persistence in the pain management system,” the study explained.

Now that data confirmed cognitive processes as a contributor to pain, it opens the door healthcare workers to tackle the problem on a different level.

Related Videos
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
© 2024 MJH Life Sciences

All rights reserved.